Literature DB >> 27910857

Myeloid-derived suppressor cells and their role in pancreatic cancer.

M Pergamo1, G Miller1.   

Abstract

Pancreatic cancer is a devastating disease and ranks as the third most common cause of cancer-related death. Like many cancers, there has been increased interest in the role of the immune system in the progression and development of pancreatic cancer. In particular, immunosuppression within the tumor microenvironment (TME) is thought to impair the host's antitumor response. In this article, we review myeloid-derived suppressor cells and their contribution to this immunosuppression within the pancreatic TME.

Entities:  

Mesh:

Year:  2016        PMID: 27910857     DOI: 10.1038/cgt.2016.65

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  81 in total

Review 1.  Alterations in macrophages and monocytes from tumor-bearing mice: evidence of local and systemic immune impairment.

Authors:  Marta Torroella-Kouri; Dayron Rodríguez; Raul Caso
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

2.  miRNA dynamics in tumor-infiltrating myeloid cells modulating tumor progression in pancreatic cancer.

Authors:  Leonie Mühlberg; Benjamin Kühnemuth; Eithne Costello; Victoria Shaw; Bence Sipos; Magdalena Huber; Heidi Griesmann; Sebastian Krug; Marvin Schober; Thomas M Gress; Patrick Michl
Journal:  Oncoimmunology       Date:  2016-05-09       Impact factor: 8.110

Review 3.  Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators.

Authors:  A Ben-Baruch
Journal:  Semin Cancer Biol       Date:  2005-08-31       Impact factor: 15.707

4.  Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells.

Authors:  Svetlana Karakhanova; Julia Link; Moritz Heinrich; Ivan Shevchenko; Yuhui Yang; Matthias Hassenpflug; Henriette Bunge; Katharina von Ahn; Ramona Brecht; Andreas Mathes; Caroline Maier; Viktor Umansky; Jens Werner; Alexandr V Bazhin
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

5.  Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways.

Authors:  Jessica M Haverkamp; Amber M Smith; Ricardo Weinlich; Christopher P Dillon; Joseph E Qualls; Geoffrey Neale; Brian Koss; Young Kim; Vincenzo Bronte; Marco J Herold; Douglas R Green; Joseph T Opferman; Peter J Murray
Journal:  Immunity       Date:  2014-12-11       Impact factor: 31.745

Review 6.  The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity.

Authors:  Je-In Youn; Dmitry I Gabrilovich
Journal:  Eur J Immunol       Date:  2010-11       Impact factor: 5.532

Review 7.  Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells.

Authors:  Michael Friberg Bruun Nielsen; Michael Bau Mortensen; Sönke Detlefsen
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

8.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

9.  Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.

Authors:  Bin Zhang; Zhijun Wang; Liangliang Wu; Meng Zhang; Wei Li; Jianhua Ding; Jun Zhu; Huafeng Wei; Ke Zhao
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

10.  Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression.

Authors:  Laura Pinton; Samantha Solito; Vera Damuzzo; Samuela Francescato; Assunta Pozzuoli; Antonio Berizzi; Simone Mocellin; Carlo Riccardo Rossi; Vincenzo Bronte; Susanna Mandruzzato
Journal:  Oncotarget       Date:  2016-01-12
View more
  39 in total

Review 1.  Cancer Manipulation of Host Physiology: Lessons from Pancreatic Cancer.

Authors:  Constantinos P Zambirinis; George Miller
Journal:  Trends Mol Med       Date:  2017-04-08       Impact factor: 11.951

2.  Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.

Authors:  Fangxuan Li; Yang Zhao; Lijuan Wei; Shixia Li; Juntian Liu
Journal:  Cancer Biol Ther       Date:  2018-05-08       Impact factor: 4.742

3.  Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype.

Authors:  Simone Borgoni; Andrea Iannello; Santina Cutrupi; Paola Allavena; Maurizio D'Incalci; Francesco Novelli; Paola Cappello
Journal:  Oncoimmunology       Date:  2017-11-13       Impact factor: 8.110

Review 4.  Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.

Authors:  Meredith L Stone; Gregory L Beatty
Journal:  Pharmacol Ther       Date:  2019-05-31       Impact factor: 12.310

5.  B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer.

Authors:  Bhalchandra Mirlekar; Daniel Michaud; Samuel J Lee; Nancy P Kren; Cameron Harris; Kevin Greene; Emily C Goldman; Gaorav P Gupta; Ryan C Fields; William G Hawkins; David G DeNardo; Naim U Rashid; Jen Jen Yeh; Autumn J McRee; Benjamin G Vincent; Dario A A Vignali; Yuliya Pylayeva-Gupta
Journal:  Cancer Immunol Res       Date:  2020-02-05       Impact factor: 11.151

6.  Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer.

Authors:  Alex B Blair; Victoria M Kim; Stephen T Muth; May Tun Saung; Nathalie Lokker; Barbara Blouw; Todd D Armstrong; Elizabeth M Jaffee; Takahiro Tsujikawa; Lisa M Coussens; Jin He; Richard A Burkhart; Christopher L Wolfgang; Lei Zheng
Journal:  Clin Cancer Res       Date:  2019-06-11       Impact factor: 12.531

7.  IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer.

Authors:  Bhalchandra Mirlekar; Daniel Michaud; Ryan Searcy; Kevin Greene; Yuliya Pylayeva-Gupta
Journal:  Cancer Immunol Res       Date:  2018-07-06       Impact factor: 11.151

8.  Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer.

Authors:  Li Xiao; Ulrike Erb; Kun Zhao; Thilo Hackert; Margot Zöller
Journal:  Oncoimmunology       Date:  2017-04-20       Impact factor: 8.110

9.  Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer.

Authors:  Jian Ye; Bradley N Mills; Tony Zhao; Booyeon J Han; Joseph D Murphy; Ankit P Patel; Carl J Johnston; Edith M Lord; Brian A Belt; David C Linehan; Scott A Gerber
Journal:  Cancer Immunol Res       Date:  2019-11-12       Impact factor: 11.151

Review 10.  Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications.

Authors:  Jun Wei; Peiwen Chen; Pravesh Gupta; Martina Ott; Daniel Zamler; Cynthia Kassab; Krishna P Bhat; Michael A Curran; John F de Groot; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.